Stocks and Investing
Stocks and Investing
Wed, March 8, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, March 7, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Dane Leone Maintained (BBIO) at Buy with Increased Target to $29 on, Mar 7th, 2023
Dane Leone of Raymond James, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Increased Target from $17 to $29 on, Mar 7th, 2023.
Dane has made no other calls on BBIO in the last 4 months.
There are 2 other peers that have a rating on BBIO. Out of the 2 peers that are also analyzing BBIO, 0 agree with Dane's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Dane
- Tyler Van Buren of "Cowen & Co." Initiated at Buy on, Monday, February 6th, 2023
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Decreased Target to $19 on, Monday, January 23rd, 2023
Contributing Sources